Drug Trial Radar · NCT06149286
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
580
Planned (sponsor's estimate)
Start
Dec 28, 2023
Primary completion
Apr 30, 2031
Study completion Apr 30, 2031
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Nov 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL) that has come back after treatment (called "relapsed") or did not respond to treatment (called "refractory"). FL and MZL are subtypes of Non-Hodgkin 's Lymphoma (NHL). This study will be made up of two parts (Part 1 not randomized, Part 2 randomized - controlled). The aim of Part 1 of the study is to see how safe and tolerable the study drug is when used in combination with lenalidomide, in participants with FL or MZL, and to determine the dose of the study drug to be used in Part 2 of this study. This combination is considered "first-in-human" as it has not been tested as a combination treatment in humans before. The aim of Part 2, of the study is to assess how well the combination of the study drug and lenalidomide works compared to the combination of rituximab (called "the comparator drug") and lenalidomide. The combination of comparator drug and lenalidomide is the current standard-of-care treatment for relapsed/refractory FL and/or MZL. Standard-of-care means the usual medication expected and used when receiving treatment for a condition. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug in combination with lenalidomide * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects) * The impact from the study drug on quality-of-life and ability to complete routine daily activities
Conditions
- Relapsed/Refractory Follicular Lymphoma
- Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
Interventions
OdronextamabDrug
Administered per the protocol
LenalidomideDrug
Administered per the protocol
RituximabDrug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose Limiting Toxicities (DLTs) for odronextamab in combination with lenalidomideTime frame: Up to 35 days
- Incidence of Treatment Emergent Adverse Events (TEAEs) for odronextamab in combination with lenalidomideTime frame: Up to 2 years
- Severity of TEAEs for odronextamab in combination with lenalidomideTime frame: Up to 2 years
- Progression-Free Survival (PFS) as assessed by Independent Central Review (ICR)Time frame: Up to 5 years
Locations
172 sites in 18 countries. Site status is shown where the registry gives one.
David Geffen School of Medicine at UCLA
Los Angeles, California · Recruiting
Boca Raton Clinical Research (BRCR) Global
Plantation, Florida · Recruiting
Indiana University and Comprehensive Cancer Center
Indianapolis, Indiana · Recruiting
Hattiesburg Clinic
Hattiesburg, Mississippi · Recruiting
Dartmouth Cancer Center
Lebanon, New Hampshire · Recruiting
Stony Brook University Hospital
Stony Brook, New York · Recruiting
Clinical Research Alliance Inc
Westbury, New York · Withdrawn
East Carolina University
Greenville, North Carolina · Recruiting
Prohealth Care Inc
Waukesha, Wisconsin · Recruiting
Liverpool Hospital
Liverpool, New South Wales, Australia · Recruiting
Calvary Mater Newcastle
Waratah, New South Wales, Australia · Recruiting
Pindara Private Hospital
Benowa, Queensland, Australia · Recruiting
Royal Hobart Hospital
Hobart, Tasmania, Australia · Recruiting
Epworth Freemasons
East Melbourne, Victoria, Australia · Recruiting
Medical University Vienna
Vienna, Austria · Recruiting
Klinikum Wels-Grieskirchen
Wels, Austria · Recruiting
Ordensklinikum Linz
Linz, Osterreich, Austria · Recruiting
Kepler University Hospital
Linz, Upper Austria, Austria · Recruiting
Ziekenhuis Netwerk Antwerpen Stuivenberg
Antwerp, Belgium · Recruiting
Institut Jules Bordet
Brussels, Belgium · Recruiting
Centre Hospitalier Universitaire at Universite Catholique de Louvain Namur
Yvoir, Namur, Belgium · Recruiting
Universitair Ziekenhuis (UZ) Gent/ Ghent University Hospital
Ghent, Oost-Vlaanderen, Belgium · Recruiting
Algemeen Ziekenhuis AZ Delta
Roeselare, West-Vlaanderen, Belgium · Recruiting
Instituto Nacional de Cancer Jose Alencar Gomes da Silva
Rio de Janeiro, Brazil · Recruiting
Hospital Sirio Libanes
São Paulo, Brazil · Recruiting
A Beneficencia Portuguesa de Sao Paulo, Oncology House
São Paulo, Brazil · Recruiting
Hospital Sao Rafael
Salvador, Estado de Bahia, Brazil · Recruiting
Hospital Sirio Libanes Brasilia
Brasília, Federal District, Brazil · Recruiting
Uopeccan Hospital do Cancer de Cascavel
Cascavel, Paraná, Brazil · Recruiting
Hospital Erasto Gaertner
Curitiba, Paraná, Brazil · Recruiting
Hospital de Clinicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Centro Gaucho Integrado
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Amaral Carvalho Hospital
Jaú, São Paulo, Brazil · Recruiting
Fakultni Nemocnice Brno
Brno, Czechia · Recruiting
University Hospital Kralovske Vinohrady
Prague, Czechia · Recruiting
Vseobecna Fakultni Nemocnice V Praze
Prague, Czechia · Recruiting
University Hospital Hradec Kralove
Hradec Králové, East Bohemia, Czechia · Recruiting
Centre Hospitalier d'Avignon
Avignon, France · Recruiting
Centre Hospitalier Universitaire (CHU) Montpellier
Montpellier, France · Recruiting
Hopital Saint Louis
Paris, France · Recruiting
Showing 40 of 172 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.